This inventor holds 1 USPTO granted patent. Top assignee: Technical University of Munich. Active years: 2023.
Company Filing History:
Years Active: 2023
Title: Adam M Chaker: Innovator in Allergen-Specific Immunotherapy
Introduction: Adam M Chaker is a notable inventor based in Munich, Germany. He has made significant contributions to the field of allergen-specific immunotherapy. His work focuses on predicting therapeutic success in patients suffering from allergic diseases.
Latest Patents: Adam M Chaker holds 1 patent titled "Ratio of immune cells as prognostic indicator of therapeutic success in allergen-specific immunotherapy." This invention relates to a method of predicting the therapeutic success of allergen-specific immunotherapy (AIT) in patients with allergic diseases. The patent also includes a kit designed for the same purpose, enhancing the ability to forecast treatment outcomes.
Career Highlights: Adam M Chaker is affiliated with the Technical University of Munich, where he conducts research and develops innovative solutions in immunotherapy. His work has the potential to improve the quality of life for many individuals suffering from allergies.
Collaborations: Some of his notable coworkers include Constanze A Jakwerth and Carsten Schmidt-Weber. Their collaborative efforts contribute to advancing research in the field of allergen-specific immunotherapy.
Conclusion: Adam M Chaker's innovative work in allergen-specific immunotherapy showcases his commitment to improving patient outcomes through scientific research and invention. His contributions are vital in the ongoing battle against allergic diseases.